RxDoctor Payments Data

Umar Ahmad, DO

Endocrinology, Diabetes & Metabolism · Danbury, CTNPI 1336589746

Payments from drug & device makers

$215in general payments, 2019–2025

Across 9 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$91
  • Ultragenyx Pharmaceutical Inc.$46
  • Sequel Med Tech, LLC$26
  • Insulet Corporation$20
  • Medtronic$19
  • Lilly USA, LLC$12

What the payments were for

  • Food & beverage$20395%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$215 in reported general payments places this provider in the 20th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut

Medicare billing

Part B allowed, 2024
$145,651
Medicare patients
526
Services billed
2,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide313$547,651
MounjaroTirzepatide246$378,552
JardianceEmpagliflozin249$341,558
TrulicityDulaglutide143$245,507
Tresiba Flextouch U-200Insulin Degludec70$93,354
JanuviaSitagliptin Phosphate58$88,138
Xultophy 100-3.6Insulin Degludec/Liraglutide56$83,148
Tresiba Flextouch U-100Insulin Degludec97$70,885
FarxigaDapagliflozin Propanediol45$59,705
Humalog Kwikpen U-100Insulin Lispro121$41,866
TradjentaLinagliptin32$39,952
ProliaDenosumab23$39,824
Lantus SolostarInsulin Glargine,hum.Rec.Anlog254$39,728
Fiasp FlextouchInsulin Aspart (Niacinamide)23$32,350
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog59$28,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog$12$639,816428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

Other endocrinology, diabetes & metabolism in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →